## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person – HOLBROOK KAREN A				2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]									S. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X. Director 10% Owner				
(Last) (First) (Middle) 875 TARAWITT DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 09/06/2017													)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							ar)	_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				e)
LONGBOAT KEY, FL 34228 (City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Execution any	2A. Deemed Execution Date, if			nsaction 8)	4. Se or Di (Instr	Securities Acquir Disposed of (D) nstr. 3, 4 and 5)		ired (A) 5. Amount of Beneficially Reported Transfer (Instr. 3 and		of Securities Owned Following ansaction(s) 4)		Ownership of Gorm: Direct (D) or Indirect (I)	. Nature of Indirect Beneficial Ownership Instr. 4)
Common Stock 09/06/2017						S			,059 D		Price 1.7272 91	14	I		Instr. 4)		
Reminder:	Report on a	separate line for o	each class of securiti					Per cor for	rsons ntaine m dis	who resed in this	for	m are not ently vali	t require d OMB c	n of inform d to respo ontrol nur	nd unless t		74 (9-02)
						ılls, w	arrant	s, option	s, con	vertible s	ecur	eficially O	wned	1			
			3A. Deemed Execution Date, ar) (Month/Day/Yea	Code		tion of Deriva		Expiration (Month/I mitted or cosed or				7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
				Code	e V	/ (A)	) (D)	Date Exercis	able	Expiratio Date	'n	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 101.19							<u>(2</u>	<u>(7</u>	10/26/20	026	Common Stock	3,985		3,985	D	
Stock Option (right to buy)	\$ 91.78							10/30/	2014	10/30/20	024	Common Stock	4,000		4,000	D	
Stock Option (right to buy)	\$ 87.39							10/31/	2013	10/30/20	023	Common Stock	4,000		4,000	D	
Stock Option (right to buy)	\$ 87.34							10/29/	2016	10/28/20	025	Common Stock	4,260		4,260	D	
Stock Option (right to buy)	\$ 70.35							10/27/	2011	10/26/20	021	Common Stock	5,000		5,000	D	
Stock Option (right to buy)	\$ 66.9							10/25/	2012	10/24/20	022	Common Stock	5,000		5,000	D	
Stock Option (right to buy)	\$ 65.47							10/23/	2008	10/22/20	018	Common Stock	5,000		5,000	D	
Stock																	

Option (right to buy)	\$ 63.03				10/29/2009	10/28/2019	Common Stock	5,000	5,000	D	
Stock Option (right to buy)	\$ 61.46				10/28/2010	10/27/2020	Common Stock	5,000	5,000	D	

### **Reporting Owners**

D # 0 N /411	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
HOLBROOK KAREN A 875 TARAWITT DRIVE LONGBOAT KEY, FL 34228	X								

### **Signatures**

/s/ Brenda S. Furlow, attorney in fact for Karen A. Holbrook pursuant to Power of Attorney previously filed	09/08/2017
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$121.72 to \$121.728, inclusive. The reporting (1) person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (2) The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.